InnoCan Pharma (DE:IP40)
FRANKFURT:IP40
IP40 Stock Chart & Stats
€10.50
--
Market closed
€10.50
--
Day’s Range― - ―
52-Week Range€1.70 - €13.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)913.00
Market Cap
€9.11M
Enterprise Value€6.51M
Total Cash (Recent Filing)€6.68M
Total Debt (Recent Filing)€1.42M
Price to Earnings (P/E)―
Beta0.05
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding4,498,772
10 Day Avg. Volume1,148
30 Day Avg. Volume913
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)3.90
Price to Sales (P/S)0.82
P/FCF Ratio45.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~90% gross margins indicate exceptionally strong unit economics for InnoCan's products and delivery platforms. This margin buffer can absorb operating expenses during scaling, support profitability once SG&A/R&D are controlled, and enable sustainable pricing power over months to years.
Moderate Balance Sheet LeverageA debt-to-equity of ~0.27 with meaningful assets and equity provides financial flexibility and runway relative to peers. Moderate leverage reduces near-term insolvency risk, allowing continued R&D and commercialization activity while management works to return to positive cash flow.
Proprietary Cannabinoid Delivery FocusThe company's niche in cannabinoid therapeutics and proprietary controlled‑release delivery technology creates a differentiated product roadmap. This structural specialization builds potential competitive barriers, addressable human and veterinary markets, and long‑term licensing or product revenue opportunities if clinical/regulatory milestones proceed.
Bears Say
Ongoing Operating LossesPersistent operating losses mean gross profits are insufficient to cover operating expenses. Over months, continued unprofitability stresses capital reserves, limits reinvestment capacity, and increases dependence on external funding, undermining durability of current operations absent a credible path to sustained operating profit.
Negative Operating And Free Cash FlowConsistent negative OCF and sharply declining free cash flow demonstrate the business is burning cash rather than generating it. This elevates funding risk, may force dilutive financing or constrain product development and commercialization, and reduces the company's ability to capitalize on its high gross margins.
Revenue Growth Slowing/decliningAfter several years of ramp, TTM revenue has started to decline, signaling loss of momentum in core sales or market penetration. Slowing top-line growth limits operating leverage, makes fixed costs harder to cover, and lengthens the timeline to profitability absent renewed, sustainable revenue expansion.
InnoCan Pharma News
IP40 FAQ
What was InnoCan Pharma’s price range in the past 12 months?
InnoCan Pharma lowest stock price was €1.70 and its highest was €13.20 in the past 12 months.
What is InnoCan Pharma’s market cap?
InnoCan Pharma’s market cap is €9.11M.
When is InnoCan Pharma’s upcoming earnings report date?
InnoCan Pharma’s upcoming earnings report date is Aug 31, 2026 which is in 86 days.
How were InnoCan Pharma’s earnings last quarter?
InnoCan Pharma released its earnings results on May 27, 2026. The company reported -€0.184 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.184.
Is InnoCan Pharma overvalued?
According to Wall Street analysts InnoCan Pharma’s price is currently Overvalued.
Does InnoCan Pharma pay dividends?
InnoCan Pharma does not currently pay dividends.
What is InnoCan Pharma’s EPS estimate?
InnoCan Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCan Pharma have?
InnoCan Pharma has 4,498,772 shares outstanding.
What happened to InnoCan Pharma’s price movement after its last earnings report?
InnoCan Pharma reported an EPS of -€0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 27.647%.
Which hedge fund is a major shareholder of InnoCan Pharma?
Currently, no hedge funds are holding shares in DE:IP40
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
InnoCan Pharma
InnoCan Pharma Corporation, a pharmaceutical company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Poland, France, and internationally. The company engages in the research and development of COVID-19 and other condition treatment by using CBD loaded exosomes; and CBD loaded liposomes. Its product includes CBD eye serum, CBD face oil, CBD face cream, CBD facial serum, CBD sleeping mask, CBD recovery lotion, and the Relief & Go spray. The company is also involved in the commercialization and sale of branded CBD integrated pharmaceutical and topical treatment products. InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.
Technical Analysis
Willow Biosciences Inc
―
Quantum Biopharma
―
MediPharm Labs
―
Voyageur Pharmaceuticals
―
Avicanna
―
Options Prices
Currently, No data available
---